Moderna reported Q3 2024 revenues of $1.9 billion with net income of $13 million, or $0.03 per share. Product sales reached $1.8 billion, including $1.8 billion from Spikevax and $10 million from mRESVIA. The company maintains its 2024 product sales guidance of $3.0-3.5 billion.Cost efficiency improvements were evident as cost of sales decreased 77% YoY to $514 million, while R&D expenses fell 2% to $1.1 billion and SG&A expenses dropped 36% to $281 million. Cash position stood at $9.2 billion as of September 30, 2024.The company expanded its Executive Committee with Stephen Hoge taking additional commercial responsibilities as President, while Rose Loughlin and Jacqueline Miller were promoted to lead research and development organizations respectively. Moderna remains focused on delivering 10 product approvals over the next three years, with plans to file for approval of its next-generation COVID-19 vaccine and RSV vaccine for high-risk adults in 2024.

Moderna reported Q3 2024 revenues of $1.9 billion with net income of $13 million, or $0.03 per share. Product sales reached $1.8 billion, including $1.8 billion from Spikevax and $10 million from mRESVIA. The company maintains its 2024 product sales guidance of $3.0-3.5 billion.Cost efficiency improvements were evident as cost of sales decreased 77% YoY to $514 million, while R&D expenses fell 2% to $1.1 billion and SG&A expenses dropped 36% to $281 million. Cash position stood at $9.2 billion as of September 30, 2024.The company expanded its Executive Committee with Stephen Hoge taking additional commercial responsibilities as President, while Rose Loughlin and Jacqueline Miller were promoted to lead research and development organizations respectively. Moderna remains focused on delivering 10 product approvals over the next three years, with plans to file for approval of its next-generation COVID-19 vaccine and RSV vaccine for high-risk adults in 2024.